Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?:
Abstract
1061988 TAM0010.1177/17588359211061988Therapeutic Advances in Medical OncologyA Donia, R Shahid et al. research-article20212021 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Can we develop oncolytic SARS-CoV-2 to 2021, Vol. 13: 1 –2 h DOI: 10.1177/ ttps://doi.org/10.1177 /17588359211061988 https://doi.org/10.1177/17588359211061988 specifically target cancer cells? © The Author(s), 2021. Article reuse guidelines: sagepub.com/journals- Ahmed Donia , Ramla Shahid, Muhammad Nawaz, Tahir Yaqub and permissions Habib Bokhari Correspondence to: Dear Editor inflammatory cytokines secreted in response to Ahmed Donia infection. Sollini and colleagues recently reported Department of Biosciences, Faculty We read with great interest the article by Ottaiano that a 61-year-old patient had complete remission of Science, COMSATS et al. titled “Unexpected tumor reduction in metastatic of follicular lymphoma after SARS-CoV-2 infec- University Islamabad, Islamabad 45550, Pakistan colorectal cancer patients during SARS-Cov-2 infec- tion, with exclusion of malignancy guided by ahmeddonia123@yahoo. tion” reporting a very interesting three colorectal computed tomography (CT) biopsy performed com cancer (mCRC) cases experiencing infection by twice. Habib Bokhari Department of severe acute respiratory syndrome coronavirus 2 Biosciences, Faculty (SARS-Cov-2), and all three patients surprisingly Keeping in mind the current cases of cancer of Science, COMSATS University Islamabad, showed improvement in mCRC disease burden. remission seen